Cargando…
Myasthenic crisis following SARS-CoV-2 infection and delayed virus clearance in a patient treated with rituximab: clinical course and 6-month follow-up
Autores principales: | Wanschitz, Julia V., Kaml, Manuela, Pfausler, Bettina, Helbok, Raimund, Wildner, Sophie, Widmann, Gerlig, Sahanic, Sabina, Deisenhammer, Florian, Löscher, Wolfgang N., Reindl, Markus, Löffler-Ragg, Judith, Beer, Ronny |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678580/ https://www.ncbi.nlm.nih.gov/pubmed/33216224 http://dx.doi.org/10.1007/s00415-020-10310-x |
Ejemplares similares
-
Guillain‐Barré syndrome in a patient with antibodies against SARS‐COV‐2
por: Helbok, R., et al.
Publicado: (2020) -
IgG-index predicts neurological morbidity in patients with infectious central nervous system diseases
por: Lackner, Peter, et al.
Publicado: (2010) -
Caspr2 antibodies in herpes simplex encephalitis: an extension of the spectrum of virus induced autoimmunity? – A case report
por: Berek, Klaus, et al.
Publicado: (2022) -
Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study
por: Rass, Verena, et al.
Publicado: (2022) -
Impact of Vitamin D Deficiency on COVID-19—A Prospective Analysis from the CovILD Registry
por: Pizzini, Alex, et al.
Publicado: (2020)